

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6167116

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
EA PHARMA CO., LTD.	05/15/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ELOBIX AB
<b>Street Address:</b>	ARVID WALLGRENS BACKE 20
<b>City:</b>	GÖTEBORG
<b>State/Country:</b>	SWEDEN
<b>Postal Code:</b>	413 46
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16901800
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	+1 (612) 638-5719
<b>Email:</b>	krahler@fr.com, apsi@fr.com
<b>Correspondent Name:</b>	ALYSHA A. DICKE
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	44933-0004002
<b>NAME OF SUBMITTER:</b>	NIKKI KRAHLER
<b>SIGNATURE:</b>	/Nikki Krahler/
<b>DATE SIGNED:</b>	06/23/2020
<b>Total Attachments: 3</b>	
source=44933-0004002_C2CAssignment#page1.tif	
source=44933-0004002_C2CAssignment#page2.tif	
source=44933-0004002_C2CAssignment#page3.tif	

Attorney Docket No. 44442-0003US1 Assignment

from EA Pharma Co., Ltd. to ELOBIX AB

ASSIGNMENT

Assignor: EA Pharma Co., Ltd.  
a corporation organized and existing under the laws of Japan, and having a place of  
business at:  
2-1-1, Irifune, Chuo-ku,  
Tokyo 104-0042 Japan

Assignee: ELOBIX AB  
a corporation organized and existing under the laws of Sweden, and having a place of  
business at:  
Arvid Wallgrens Backe 20  
S-413 46 Göteborg  
SWEDEN

Country	Application No.	Filing Date	Title
United States	15/320,621	12/20/2016	SOLID FORMULATION AND METHOD FOR PREVENTING OR REDUCING COLORATION THEREOF

1. Assignor represents that it is the owner of the patent application listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patent application listed above (the "Patent Application") and of all new and useful inventions and improvements that are disclosed in the Patent Application (the "Inventions"). The Patent Application and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in its own name wherever so permitted by law or in the name of Assignee wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to the Patent Application pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

03p-67082

Assignment for the US

2/3

Attorney Docket No. 44442-0003US1 Assignment  
from EA Pharma Co., Ltd. to ELOBIX AB

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patent Application, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patent Application, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

OSP-67022  
Assignment for the US  
3/3

Attorney Docket No. 44442-0003US1 Assignment  
from EA Pharma Co., Ltd. to ELOBIX AB

The Assignor hereby executes this Assignment.

Assignor: EA Pharma Co., Ltd.

Signature: *T. Ishiguro*

Date: May 15, 2017

Name: Tsuneo ISHIGURO

Title: General Manager Intellectual Property Dept.

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: ELOBIX AB

Signature: *[Signature]*

Date: May 29, 2017

Name: Jon Mattsson

Title: Director

61478397.doc